About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 7304 record(s)
Req # A-2023-001572
Any security related training completed by Nadine Huggins, the Senior Assistant Deputy Minister (ADM) and Chief Security officer at Health Canada.Organization: Health Canada
May 2024
Req # A-2023-001628
All communications originating from atrazine registrants, or their agents or representatives including the triazine network to the Pest Management Regulatory Agency (PMRA) regarding the aquatic reference values for atrazine and all PMRA internal emails and memoranda discussing those communications. Time period is January 1, 2023 to March 28, 2024.Organization: Health Canada
May 2024
Req # A-2024-000044
Documents and records containing information regarding the mock-ups of every label to be used in connection with the Fourth Desmopressin Abbreviated New Drug Submission (ANDS) and mock-ups of the drug product’s packages, as described in the Food and Drug Regulations.Organization: Health Canada
May 2024
Req # A-2024-000045
The most recent Module 2.3: Quality Overall Summary (QOS) submitted by the sponsor for the Fourth Desmopressin Abbreviated New Drug Submission (ANDS).Organization: Health Canada
May 2024
Req # A-2024-000046
Any Canadian Reference Product Confirmation submitted by the sponsor of the Fourth Desmopressin Abbreviated New Drug Submission (ANDS).Organization: Health Canada
May 2024
Req # A-2024-000050
If the Fourth Desmopressin Abbreviated New Drug Submission (ANDS) has received, a Screening Acceptance Letter, a Notice of Deficiency (NOD), a Notice of Non-Compliance (NON), a NOD-Withdrawal (NODW), a NON-Withdrawal (NON-W), provide the month and year that the notice was issued; and provide a copy of the correspondence.Organization: Health Canada
May 2024
Req # A-2024-000051
The Abbreviated New Drug Submission (ANDS) cover letter of the company who submitted the Fourth Desmopressin ANDS.Organization: Health Canada
May 2024
Req # A-2024-000052
In respect of the desmopressin acetate submission which was removed from the Generic Submissions Under Review (GSUR) List some time between February 22, 2024 and March 18, 2024, the year and month in which the Abbreviated New Drug Submission (ANDS) was accepted for review.Organization: Health Canada
May 2024
Req # A-2024-000053
The Product Information Template: Regulatory Enrollment Process for the Fourth Desmopressin Abbreviated New Drug Submission (ANDS) , setting out the proposed indication(s)/use(s) of the drug product.Organization: Health Canada
May 2024
Req # A-2024-000054
The name of the company who submitted the Fourth Desmopressin Abbreviated New Drug Submission (ANDS).Organization: Health Canada
May 2024